SCHEMBL19902595

SCHEMBL19902595

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1cnn2cc(CN3CCOCC3)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.43
FGFR1 P11362 1/20 0.42
FGFR2 P21802 1/20 0.42
FGFR3 P22607 1/20 0.42
CNR1 P21554 2/20 0.41
CNR2 P34972 2/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAOB P27338 1/20 0.38
DRD4 P21917 4/20 0.38
ALDH1A1 P00352 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ROCK1 Q13464 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
JAK3 P52333 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19902408 0.91 CNR2 (0.43) ROCK2CNR1CNR2DRD4TYK2
SCHEMBL17452732 0.90 ROCK2 (0.56) ROCK2FGFR1FGFR2FGFR3CNR1
SCHEMBL19902569 0.87 ROCK2 (0.47) ROCK2KDM4EALDH1A1HSD17B10ROCK1
SCHEMBL19902409 0.84 ROCK2 (0.45) ROCK2KDM4EALDH1A1HSD17B10ROCK1
SCHEMBL19902419 0.82 ROCK2 (0.45) ROCK2KDM4EALDH1A1HSD17B10ROCK1
SCHEMBL17452726 0.82 ROCK2 (0.53) ROCK2CNR1CNR2KDM4EDRD4
SCHEMBL20229746 0.81 ROCK2 (0.42) ROCK2KDM4EALDH1A1HSD17B10ROCK1
SCHEMBL19902414 0.81 ROCK2 (0.42) ROCK2KDM4EALDH1A1HSD17B10ROCK1
SCHEMBL19902603 0.81 ROCK2 (0.49) ROCK2KDM4ENPC1RAB9AKMT2A
SCHEMBL19902613 0.80 ROCK2 (0.48) ROCK2KDM4ENPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 ROCK2 3/4885FGFR1 686/4885FGFR2 696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.